Prevention of bone loss with alendronate in postmenopausal women under 60 years of age

New England Journal of Medicine

Volumn 338, Issue 8, 1998, Pages 485-492

  Hosking, David ^a   Chilvers, Clair E D ^b   Christiansen, Claus ^c   Ravn, Pernille ^c   Wasnich, Richard ^d   Ross, Philip ^d   Mcclung, Michael ^e   Balske, Ana ^e   Thompson, Desmond ^f   Daley, Marianne ^f   Yates, A John ^f  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d Hawaii Osteoporosis Center   (United States)

^e EARLE A CHILES RESEARCH INSTITUTE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; TRISEQUENS;

ABSORPTIOMETRY; ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ALENDRONATE; BONE DENSITY; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOREARM; HUMANS; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PELVIC BONES; POSTMENOPAUSE; PROGESTERONE CONGENERS;

EID: 0346344235     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802193380801     Document Type: Article

References (28)

1. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7. [Erratum, N Engl J Med 1993;328:65.]
2. Black DM, Cummings SR, Melton LJ III. Appendicular bone mineral and a woman's lifetime risk of hip fracture. J Bone Miner Res 1992;7:639-46.
3. Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3: 113-9.
4. Dempster DW, Shane E, Horbert W, Lindsay R. A simple method for correlative light and scanning electron microscopy of human iliac crest bone biopsies: qualitative observations in normal and osteoporotic subjects. J Bone Miner Res 1986;1:15-21.
5. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-40.
6. Horsman A, Gallagher JC, Simpson M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 1977;2:789-92.
7. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
8. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92.
9. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.
10. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risk and costs. Br Med Bull 1992;48:368-400.
11. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
12. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
13. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322:1265-71.
14. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
15. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
16. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993;3:Suppl 3:S7-S12.
17. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-86.
18. Devogelaer JP, Broll H, Correa-Potter R, et al. Oral alendronate induced progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50.
19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
20. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:361-72.
21. Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. BMJ 1988;296:1150-2.
22. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund K-E, Transbol I. Prevention of early postmenopausal bone loss: a controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9.
23. Lindsay R. The menopause and osteoporosis. Obstet Gynecol 1996; 87:Suppl:16S-19S.
24. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
25. Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol 1996;87:Suppl:27S-35S.
26. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
27. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994;21:219-29.
28. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the Study of Osteoporotic Fractures. JAMA 1996;276:1404-8.